Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

First Patient Dosed in Trial of LNS8801, KEYTRUDA Combination in Advanced Cancer

americanpharmaceuticalreviewOctober 19, 2020

Tag: LNS8801 , Keytruda , Linnaeus Therapeutics , Cancer

PharmaSources Customer Service